CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Endpoints News
Original article

Roche dips into DACs with existing partner C4 Therapeutics for $20M upfront

PartnershipPositive
AI Analysis

Summary

Roche expands its decade-long partnership with C4 Therapeutics with a $20M upfront payment to develop degrader-based antibody-drug conjugates for cancer treatment.

Importance:6/10
Sentiment:
0.60
antibody-drug conjugatesdegraderscancerpartnershipupfront payment
Related Companies

Read the original article

Published by Endpoints News on April 9, 2026 2:17 PM

Read Original